Understanding the Evolution of Intranasal Vaccines

The clinical development marketplace continues to become more complex and competitive, with stricter regulatory standards and trial oversight—all the while demanding patient-centric drug development. These, and other factors, contribute to unsustainable costs and longer timelines before much-needed therapies reach the market.

Traditional drug manufacturing and drug delivery process development requires a huge time and financial investment. Pharmaceutical and biopharmaceutical leaders are leveraging the power of in silico approaches.

Pharmaceutical manufacturers are facing unprecedented challenges from supply chain disruptions, significant demand fluctuations, reliability.

Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes. Often, patient factors and insights are not considered or discovered until the later phases of drug development when dose form, dose strength, and route of administration are already decided. There is tremendous potential benefit of equipping formulators and other scientists with patient insights earlier in the development process so that the drug product can be designed to address the specific needs of target patient populations.